Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026)
Ardelyx's (ARDX) quarterly Depreciation & Amortization (CF) came in at $915000.0 in Q1 2026, up 51.99% YoY from $602000.0 in Q1 2025, and down 0.65% on a QoQ basis from $921000.0 in Q4 2025.
Ardelyx (ARDX) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $915000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 51.99% year-over-year to $915000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (up 51.21% YoY) and the FY2025 annual result came in at $3.1 million, up 48.28% from the prior year.
- Depreciation & Amortization (CF) slipped to $915000.0 in Q1 2026, from $921000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $921000.0 in Q4 2025 to a low of -$3000.0 in Q1 2023.
- A 5-year average of $498411.8 and a median of $515000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 100.65% — and 2024, when it soared 14600.0%.
- Tracing ARDX's Depreciation & Amortization (CF) over 5 years: stood at $127000.0 in 2022, then soared by 185.04% to $362000.0 in 2023, then surged by 42.27% to $515000.0 in 2024, then soared by 78.83% to $921000.0 in 2025, then declined by 0.65% to $915000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $915000.0 (Q1 2026), $921000.0 (Q4 2025), and $905000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 604,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 604,000.00 |
| Jun 30, 2026 | 604,000.00 |
| Mar 31, 2026 | 915,000.00 |
| Mar 31, 2026 | 915,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Sep 30, 2025 | 905,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Jun 30, 2025 | 631,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Dec 31, 2024 | 515,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Sep 30, 2024 | 544,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Jun 30, 2024 | 569,000.00 |
| Mar 31, 2024 | 435,000.00 |
| Mar 31, 2024 | 435,000.00 |